Product Description: Cemdisiran sodium is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.
Applications: COVID-19-immunoregulation
Formula: C542H665F17N169Na46O330P45S6
References: [1]Badri P, Jiang X, Borodovsky A, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365-378./[2]Prajakta Badri, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365-378.
Molecular Weight: 17793.70
Compound Purity: 96.02
Research Area: Others
Solubility: 10 mM in H2O
Target: Complement System
Deutsch
English
